30 April 2019 - Phoenix Tissue Repair today announced that the U.S. FDA has granted fast track designation for PTR-01, an investigational protein replacement therapy designed to treat recessive dystrophic epidermolysis bullosa.
Recessive dystrophic epidermolysis bullosa is a rare genetic disorder associated with severe skin blistering and treatment is currently limited to palliative options.
Phoenix Tissue Repair also announced it has opened enrolment of the second cohort in its ongoing Phase 1/2 trial in adult RDEB (PTR-01-001 trial). The PTR-01-001 trial is a randomised saline-controlled, single-blind, multiple ascending dose, dose-escalation and multi-center study.